TY - JOUR
T1 - Does multimodal perioperative pain management enhance immediate and short-term outcomes after living donor partial hepatectomy? - A systematic review of the literature and expert panel recommendations
AU - Hogan, Brian J
AU - Pai, Sher-Lu
AU - Planinsic, Raymond
AU - Suh, Kyung-Suk
AU - Hillingso, Jens G
AU - Ghani, Shahi Abdul
AU - Fan, Ka Siu
AU - Spiro, Michael
AU - Raptis, Dimitri Aristotle
AU - Vohra, Vijay
AU - Auzinger, Georg
AU - ERAS4OLT.org Working Group
N1 - This article is protected by copyright. All rights reserved.
PY - 2022/10
Y1 - 2022/10
N2 - BACKGROUND: The optimal analgesic strategy for patients undergoing donor hepatectomy is not known and the potential short- and long-term physical and psychological consequences of complications are significant.OBJECTIVES: To identify whether a multimodal approach to pain of the donor intraoperatively enhances immediate and short-term outcomes after living liver donation, and to provide international expert panel recommendations.DATA SOURCES: Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.METHODS: Systematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. PROSPERO 2021 CRD42021260699.RESULTS: Nine studies assessing multi-modal analgesia strategies were included in a qualitative assessment. Interventions included local, regional, and neuro-axial anesthetic techniques, pharmacological intervention (NSAIDs, COX-2 inhibitors, ketamine, dexmedetomidine, and lidocaine), and acupuncture. Overall, there was a significant (40%) reduction in opioid requirement on day 1 and a significant reduction in pain scores in the intervention vs control groups. Significant reductions in either length of stay or post-operative complications were demonstrated in four of nine studies.CONCLUSIONS: Opioid use for patients undergoing donor hepatectomy is likely to impact both their short- and long-term outcomes. To reduce post-operative pain scores, shorten length of hospital stay, and promote earlier post-operative return of bowel function, we recommend that multi-modal analgesia be offered to patients undergoing living donor hepatectomy. Further research is required to confirm which multi-modal techniques are most associated with enhanced recovery in living liver donors.
AB - BACKGROUND: The optimal analgesic strategy for patients undergoing donor hepatectomy is not known and the potential short- and long-term physical and psychological consequences of complications are significant.OBJECTIVES: To identify whether a multimodal approach to pain of the donor intraoperatively enhances immediate and short-term outcomes after living liver donation, and to provide international expert panel recommendations.DATA SOURCES: Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.METHODS: Systematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. PROSPERO 2021 CRD42021260699.RESULTS: Nine studies assessing multi-modal analgesia strategies were included in a qualitative assessment. Interventions included local, regional, and neuro-axial anesthetic techniques, pharmacological intervention (NSAIDs, COX-2 inhibitors, ketamine, dexmedetomidine, and lidocaine), and acupuncture. Overall, there was a significant (40%) reduction in opioid requirement on day 1 and a significant reduction in pain scores in the intervention vs control groups. Significant reductions in either length of stay or post-operative complications were demonstrated in four of nine studies.CONCLUSIONS: Opioid use for patients undergoing donor hepatectomy is likely to impact both their short- and long-term outcomes. To reduce post-operative pain scores, shorten length of hospital stay, and promote earlier post-operative return of bowel function, we recommend that multi-modal analgesia be offered to patients undergoing living donor hepatectomy. Further research is required to confirm which multi-modal techniques are most associated with enhanced recovery in living liver donors.
KW - Analgesics, Opioid/therapeutic use
KW - Hepatectomy
KW - Humans
KW - Lidocaine/adverse effects
KW - Liver
KW - Pain Management/adverse effects
KW - Pain, Postoperative/chemically induced
KW - enhanced recovery after surgery
KW - pain
KW - analgesia
KW - living donor liver transplant
UR - http://www.scopus.com/inward/record.url?scp=85142256030&partnerID=8YFLogxK
U2 - 10.1111/ctr.14649
DO - 10.1111/ctr.14649
M3 - Review
C2 - 35297508
SN - 0902-0063
VL - 36
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 10
M1 - e14649
ER -